Latest news with #TiffanyChiu
Yahoo
07-07-2025
- Business
- Yahoo
AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025
VANCOUVER, British Columbia, July 07, 2025--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) will announce its second quarter 2025 financial results on Thursday, August 7, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit View source version on Contacts Inquiries Media: Tiffany Chiu; media@ +1(236)521-6774Partnering: Murray McCutcheon, Ph.D.; bd@ +1(604)559-9005Investor Relations: Peter Ahn; ir@ +1(778)729-9116 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
National Post
07-07-2025
- Business
- National Post
AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025
Article content VANCOUVER, British Columbia — AbCellera (Nasdaq: ABCL) will announce its second quarter 2025 financial results on Thursday, August 7, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. Article content A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. Article content About AbCellera Biologics Inc. Article content AbCellera Article content (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit Article content Article content Article content Article content Article content Contacts Article content Inquiries Article content Article content Media: Tiffany Chiu; Article content media@ Article content , +1(236)521-6774 Article content Article content Partnering: Murray McCutcheon, Ph.D.; Article content Article content Article content
Yahoo
11-02-2025
- Business
- Yahoo
AbCellera to Participate at Upcoming Investor Conferences in March
VANCOUVER, British Columbia, February 11, 2025--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences: 45th Annual TD Cowen Health Care Conference, March 3-5 KeyBanc Capital Markets Healthcare Forum, March 18-19 Visit AbCellera's Investor Relations website for additional information. About AbCellera Biologics Inc. AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit View source version on Contacts Inquiries Media: Tiffany Chiu; media@ +1(604)724-1242Business Development: Murray McCutcheon, Ph.D.; partnering@ +1(604)559-9005Investor Relations: Peter Ahn; ir@ +1(778)729-9116 Sign in to access your portfolio
